|
コンドウ ツネノリ
Kondou Tsunenori
近藤 恒徳 所属 医学部 医学科（附属足立医療センター） 職種 教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. |
| 掲載誌名 | 正式名：Japanese journal of clinical oncology 略 称：Jpn J Clin Oncol ISSNコード：14653621/03682811 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 46(6),pp.568-574 |
| 著者・共著者 | Ishihara Hiroki, Kondo Tsunenori, Omae Kenji, Takagi Toshio, Izuka Jumpei, Kobayashi Hirohito, Tanabe Kazunari |
| 発行年月 | 2016/03 |
| 概要 | OBJECTIVE:The present study aimed to evaluate the influence of the magnitude of best tumor shrinkage during second-line targeted therapy after first-line tyrosine kinase inhibitor failure on metastatic renal cell carcinoma prognosis.METHODS:Fifty-two patients were enrolled. The magnitude of tumor shrinkage was assessed according to the Response Evaluation Criteria in Solid Tumors v. 1.1, and evaluated as a continuous variable and by categorical classification: good responders (greater than or equal to -30%), mild responders (-0.1 to -29.9%), poor responders (0 to +19.9%) and non-responders (greater than or equal to +20% or new lesions). Overall survival and progression-free survival after second-line therapy initiation were evaluated according to the categorical classification. Factors predicting overall survival and progression-free survival were also examined.RESULTS:The mean magnitude of tumor shrinkage was -1.29%, and there were 9, 21, 11 and 11 good responders, mild responders, poor responders and non-responders, respectively. The overall survival and progression-free survival significantly improved as the magnitude of tumor shrinkage increased according to the categorical classification (overall survival: not reached, 27.8, 18.2 and 4.67 months; progression-free survival: 13.4, 8.19, 5.18 and 1.84 months, respectively; P< 0.0001 for both). For overall survival, the magnitude of tomor shrinkage was not demonstrated as an independent indicator in the multivariate analysis (P= 0.0872 for the categorical classification, P= 0.133 for the continuous variable) whereas for second-line progression-free survival, the magnitude of tumor shrinkage according to both the categorical classification and continuous variable was found to be an independent factor in the multivariate analysis (P< 0.0001 for both).CONCLUSIONS:The magnitude of tumor shrinkage is an independent predictive factor for progression-free survival, and may represent a surrogate marker for overall survival |
| DOI | 10.1093/jjco/hyw024 |
| PMID | 26962242 |